Lunai Bioworks wins expedited discovery to identify alleged naked short sellers

• Lunai Bioworks won a court order in Delaware allowing expedited third-party discovery to identify unnamed defendants it alleges engaged in “naked” short selling of its Nasdaq-listed common stock in late 2025 and the first half of 2026.
• The magistrate judge found good cause for early discovery, citing a prima facie showing on at least some claims and the need to obtain identifying information held by broker-dealers, custodians, market infrastructure entities, or market participants.
• The lawsuit, filed May 11, 2026, alleges securities fraud under Section 10(b) and Rule 10b-5, market manipulation under Section 9(a), and wire fraud as an intentional tort, seeking damages and injunctive relief.
• The case targets “John Doe” defendants pending identification through discovery, with the company signaling it may later add civil RICO claims that could increase potential damages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605220915PR_NEWS_USPR_____LA65750) on May 22, 2026, and is solely responsible for the information contained therein.